Martin David Harp

Ophthalmology Times® talked with Darius Moshfeghi, MD, about BUTTERFLEYE data trial results using aflibercept versus laser for the treatment of retinopathy of prematurity this year's ARVO meeting.

Ophthalmology Times® talked with Mary Durbin, PhD, about a convolutional neural network that provides image quality assessment at this year's ARVO meeting.

Ophthalmology Times® talked with Andrew Moshfeghi, MD, MBA, about OTX-TKI in a phase 1 study looking at patients with neovascular AMD this year's ARVO meeting.

Ophthalmology Times® talked Nevin El-Nimri, MS, OD, PhD, FAAO, about the relationship between optic disc fovea distance, axial length and disc at this year's ARVO meeting.

Ophthalmology Times® talked with David Tabano, PhD, from Genentech about the company's first real-world data readouts for faricimab in the treatment of DME at this year's ARVO meeting.

Ophthalmology Times® talked with Theresa Heath, MD, MBA, about Non-viral gene therapy targeting ABCA4 retinopathies at this year's ARVO meeting.

Ophthalmology Times® talked with Michael Ip, MD, about the 5 year follow-up of the original SCORE2 dataset from the NIH-sponsored clinical trial.at this year's ARVO meeting.

Ophthalmology Times® talked with David Brown, MD, about the PHOTON study examining the safety and efficacy of high-dose aflibercept for the treatment of diabetic macular edema (DME) at this year's ARVO meeting.

Ophthalmology Times® talked with Allen Chiang, MD, about the assessment of geographic atrophy progression from the Phase 3 OAKS and DERBY trials at this year's ARVO meeting.

Ophthalmology Times® talked with Kaushal Solanki, PhD, CEO and founder of Eyenuk, about EyeArt, an AI system cleared by the FDA to detect diabetic retinopathy at this year's ARVO meeting.

Ophthalmology Times® talked with Bruce Ksander, PhD, about epigenetic reprogramming to reverse aging and restore function to retinal ganglion cells at this year's ARVO meeting.

Ophthalmology Times® talked with Steven Carrubba, MD, about monkeypox skin disease and eye disease in patients who were immunocompromised in New York at this year's ARVO meeting.

Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.

Ophthalmology Times® talked with Christine Kay, MD, about the treatment of GUCY2D associated Leber congenital amaurosis type 1 at this year's ARVO meeting.

Ophthalmology Times® talked with Penny Asbell, MD, FACS, MBA, about the ARMOR study and antibiotic resistance at this year's ARVO meeting.

Ophthalmology Times® talked with Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

Ophthalmology Times® talked with Roger Goldberg, MD, MBA, about macular leakage area in the YOSEMITE and RHINE trials comparing faricimab to aflibercept at this year's ARVO meeting.

Ophthalmology Times® talked with Edmund Arthur, OD, PhD, FAAO, about his research on the early detection of diabetic retinopathy in underserved communities at this year's ARVO meeting.

Ophthalmology Times® talked with Jay Barth, MD, about the work at Ascidian Therapeutics and their research into developing a new way to administer gene therapy at this year's ARVO meeting.

Ophthalmology Times® talked with David Eveleth, MD, CEO and Founder of Trefoil Therapeutics about TTHX1114 in patients with Fuchs endothelial corneal dystrophy (FECD) undergoing Descemet’s Stripping Only (DSO) in combination with cataract surgery at this year's ARVO meeting.

Amir H. Kashani, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on optical coherence tomography and the assessment of cognitive impairment in Alzheimer's Disease and other related dementias.

Ophthalmology Times® talked with Mark Bullimore and discussed the control of myopia progression with low-concentration atropine from the Hong-Kong LAMP study at this year's ARVO meeting.

Ophthalmology Times® talked with T. Y. Alvin Liu, MD, about predictive AI and its uses in ophthalmology and screening of the eyes at this year's ARVO meeting.

Thomas V. Johnson, MD, PhD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at this year's ARVO meeting on retinal engineering and RGC replacement.

Ophthalmology Times® talked with Caroline Baumal, MD, about Apellis' presentations focusing on visual function, imaging and artificial intelligence at this year's ARVO meeting.

Ophthalmology Times® talked with Carl Danzig, MD, FASRS, at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.

Ophthalmology Times® talked with Deborah Ferrington, PhD, about her presentation on using human donor tissue to identify the mechanism responsible for the death of the retinal pigment epithelium.

Ophthalmology Times® talked with Roland Mattern, Director of Sales and Marketing for eSight and eSight User Gary Foster at this year's ARVO meeting about eSight Go, the new model of smart glasses for low vision enhancement

Ophthalmology Times® talked with George Magrath, MD, and Andrew Pucker, OD, MS, PhD, FAAO at this year's ARVO meeting about Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.